Victory Capital Management Inc. Cuts Holdings in Danaher Corporation (NYSE:DHR)

Victory Capital Management Inc. reduced its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 227,589 shares of the conglomerate's stock after selling 10,559 shares during the quarter. Victory Capital Management Inc.'s holdings in Danaher were worth $46,656,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock valued at $13,715,641,000 after purchasing an additional 315,912 shares during the period. Geode Capital Management LLC raised its holdings in Danaher by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank acquired a new position in shares of Danaher during the 4th quarter worth approximately $2,130,740,000. Bank of New York Mellon Corp increased its position in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after buying an additional 992,594 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Transactions at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Down 1.0%

DHR traded down $1.82 during midday trading on Monday, reaching $188.23. 5,890,257 shares of the company were exchanged, compared to its average volume of 3,532,965. The company has a market cap of $134.71 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 2.67 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company's fifty day moving average price is $196.13 and its 200 day moving average price is $204.86. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. As a group, analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.68%. Danaher's dividend payout ratio is 24.85%.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Argus reduced their price target on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday, July 11th. Royal Bank Of Canada reissued an "outperform" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Evercore ISI lowered their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, UBS Group reduced their price objective on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $248.48.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.